Antidepressants influence somatostatin levels and receptor pharmacology in brain

E Pallis; A Vasilaki; D Fehlmann; A Kastellakis; D Hoyer; C Spyraki; K Thermos

Journal article

Antidepressants influence somatostatin levels and receptor pharmacology in brain

E Pallis, A Vasilaki, D Fehlmann, A Kastellakis, D Hoyer, C Spyraki, K Thermos

Neuropsychopharmacology | Published : 2009

DOI: 10.1038/npp.2008.133

Abstract

This study investigated how the administration (acute and chronic) of the antidepressants citalopram and desmethylimipramine (DMI) influences somatostatin (somatotropin release inhibitory factor, SRIF) levels and SRIF receptor density (sst1-5) in rat brain. Animals received either of the following treatments: (1) saline for 21 days (control group), (2) saline for 20 days and citalopram or DMI for 1 day (citalopram or DMI acute groups), (3) citalopram or DMI for 21 days (citalopram or DMI chronic groups). Somatostatin levels were determined by radioimmunoassay. [125I]LTT SRIF-28 binding in the absence (labeling of sst1-5) or presence of 3 nM MK678 (labeling of sst1/4) and [125I]Tyr3 octreotid..

View full abstract

University of Melbourne Researchers

Daniel Hoyer Author

Grants

Awarded by University of Crete

Funding Acknowledgements

This work was supported by the Ministry of Education (EPEAEK Neuroscience, University of Crete) to KT and an EC contract (QLG3-CT-1999-00908) to KT and DH.